$2.89
2.48% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US68621F1021
Symbol
ORGO

Organogenesis Holdings Stock price

$2.89
-0.05 1.70% 1M
+0.13 4.71% 6M
-1.20 29.34% YTD
+0.24 9.06% 1Y
-12.57 81.31% 3Y
-3.74 56.41% 5Y
-6.86 70.36% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.07 2.48%
ISIN
US68621F1021
Symbol
ORGO
Sector

Key metrics

Market capitalization $373.86m
Enterprise Value $394.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 46.29
EV/Sales (TTM) EV/Sales 0.88
P/S ratio (TTM) P/S ratio 0.83
P/B ratio (TTM) P/B ratio 1.42
Revenue growth (TTM) Revenue growth -1.96%
Revenue (TTM) Revenue $448.39m
EBIT (operating result TTM) EBIT $13.76m
Free Cash Flow (TTM) Free Cash Flow $8.52m
Cash position $90.48m
EPS (TTM) EPS $-0.13
P/E forward negative
P/S forward 0.82
EV/Sales forward 0.87
Short interest 39.20%
Show more

Is Organogenesis Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Organogenesis Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Organogenesis Holdings forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Organogenesis Holdings forecast:

Buy
75%
Hold
25%

Financial data from Organogenesis Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
448 448
2% 2%
100%
- Direct Costs 129 129
6% 6%
29%
320 320
5% 5%
71%
- Selling and Administrative Expenses 231 231
7% 7%
51%
- Research and Development Expense 51 51
17% 17%
11%
38 38
12% 12%
9%
- Depreciation and Amortization 25 25
21% 21%
6%
EBIT (Operating Income) EBIT 14 14
42% 42%
3%
Net Profit -17 -17
265% 265%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Organogenesis Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organogenesis Holdings Stock News

Neutral
GlobeNewsWire
23 days ago
CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences:
Neutral
Seeking Alpha
about 2 months ago
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Brooks O'Neill - Lake Street Drew Ranieri - Morgan Stanley Matthew Park - Cantor Fitzgerald Operator Please stand by. We...
Neutral
GlobeNewsWire
about 2 months ago
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced a development program update for ReNu®, a cryopreserved amniotic suspension allograft (ASA), f...
More Organogenesis Holdings News

Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Head office United States
CEO Gary Gillheeney
Employees 862
Founded 1985
Website www.organogenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today